DLL4 blockade inhibits tumor growth and reduces tumor-initiating cell frequency - PubMed (original) (raw)
. 2009 Aug 7;5(2):168-77.
doi: 10.1016/j.stem.2009.05.019.
Wan-Ching Yen, Fumiko Axelrod, Jesspreet Basi, Lucas Donigian, Scott Dylla, Maureen Fitch-Bruhns, Sasha Lazetic, In-Kyung Park, Aaron Sato, Sanjeev Satyal, Xinhao Wang, Michael F Clarke, John Lewicki, Austin Gurney
Affiliations
- PMID: 19664991
- DOI: 10.1016/j.stem.2009.05.019
Free article
DLL4 blockade inhibits tumor growth and reduces tumor-initiating cell frequency
Timothy Hoey et al. Cell Stem Cell. 2009.
Free article
Abstract
Previous studies have shown that blocking DLL4 signaling reduced tumor growth by disrupting productive angiogenesis. We developed selective anti-human and anti-mouse DLL4 antibodies to dissect the mechanisms involved by analyzing the contributions of selectively targeting DLL4 in the tumor or in the host vasculature and stroma in xenograft models derived from primary human tumors. We found that each antibody inhibited tumor growth and that the combination of the two antibodies was more effective than either alone. Treatment with anti-human DLL4 inhibited the expression of Notch target genes and reduced proliferation of tumor cells. Furthermore, we found that specifically inhibiting human DLL4 in the tumor, either alone or in combination with the chemotherapeutic agent irinotecan, reduced cancer stem cell frequency, as shown by flow cytometric and in vivo tumorigenicity studies.
Comment in
- Molecular targeting of cancer stem cells.
Gupta R, Vyas P, Enver T. Gupta R, et al. Cell Stem Cell. 2009 Aug 7;5(2):125-6. doi: 10.1016/j.stem.2009.07.006. Cell Stem Cell. 2009. PMID: 19664981
Similar articles
- Dll4 Blockade in Stromal Cells Mediates Antitumor Effects in Preclinical Models of Ovarian Cancer.
Kuhnert F, Chen G, Coetzee S, Thambi N, Hickey C, Shan J, Kovalenko P, Noguera-Troise I, Smith E, Fairhurst J, Andreev J, Kirshner JR, Papadopoulos N, Thurston G. Kuhnert F, et al. Cancer Res. 2015 Oct 1;75(19):4086-96. doi: 10.1158/0008-5472.CAN-14-3773. Epub 2015 Sep 16. Cancer Res. 2015. PMID: 26377940 - Anti-DLL4 inhibits growth and reduces tumor-initiating cell frequency in colorectal tumors with oncogenic KRAS mutations.
Fischer M, Yen WC, Kapoun AM, Wang M, O'Young G, Lewicki J, Gurney A, Hoey T. Fischer M, et al. Cancer Res. 2011 Mar 1;71(5):1520-5. doi: 10.1158/0008-5472.CAN-10-2817. Epub 2010 Dec 30. Cancer Res. 2011. PMID: 21193546 - MMGZ01, an anti-DLL4 monoclonal antibody, promotes nonfunctional vessels and inhibits breast tumor growth.
Xu Z, Wang Z, Jia X, Wang L, Chen Z, Wang S, Wang M, Zhang J, Wu M. Xu Z, et al. Cancer Lett. 2016 Mar 1;372(1):118-27. doi: 10.1016/j.canlet.2015.12.025. Epub 2015 Dec 29. Cancer Lett. 2016. PMID: 26739060 - New pathways and mechanisms regulating and responding to Delta-like ligand 4-Notch signalling in tumour angiogenesis.
Oon CE, Harris AL. Oon CE, et al. Biochem Soc Trans. 2011 Dec;39(6):1612-8. doi: 10.1042/BST20110721. Biochem Soc Trans. 2011. PMID: 22103496 Review. - Monoclonal antibodies against human cancer stem cells.
Naujokat C. Naujokat C. Immunotherapy. 2014;6(3):290-308. doi: 10.2217/imt.14.4. Immunotherapy. 2014. PMID: 24762074 Review.
Cited by
- The cancer stem cell niche: how essential is the niche in regulating stemness of tumor cells?
Plaks V, Kong N, Werb Z. Plaks V, et al. Cell Stem Cell. 2015 Mar 5;16(3):225-38. doi: 10.1016/j.stem.2015.02.015. Cell Stem Cell. 2015. PMID: 25748930 Free PMC article. Review. - Cancer-wide in silico analyses using differentially expressed genes demonstrate the functions and clinical relevance of JAG, DLL, and NOTCH.
Kim JY, Hong N, Ham SW, Park S, Seo S, Kim H. Kim JY, et al. PLoS One. 2024 Jul 29;19(7):e0307943. doi: 10.1371/journal.pone.0307943. eCollection 2024. PLoS One. 2024. PMID: 39074091 Free PMC article. - Notch Partners in the Long Journey of T-ALL Pathogenesis.
Toribio ML, González-García S. Toribio ML, et al. Int J Mol Sci. 2023 Jan 10;24(2):1383. doi: 10.3390/ijms24021383. Int J Mol Sci. 2023. PMID: 36674902 Free PMC article. Review. - Interactions of melatonin with various signaling pathways: implications for cancer therapy.
Mihanfar A, Yousefi B, Azizzadeh B, Majidinia M. Mihanfar A, et al. Cancer Cell Int. 2022 Dec 29;22(1):420. doi: 10.1186/s12935-022-02825-2. Cancer Cell Int. 2022. PMID: 36581900 Free PMC article. Review. - MicroRNAs, a Promising Target for Breast Cancer Stem Cells.
Das PK, Siddika MA, Asha SY, Aktar S, Rakib MA, Khanam JA, Pillai S, Islam F. Das PK, et al. Mol Diagn Ther. 2020 Feb;24(1):69-83. doi: 10.1007/s40291-019-00439-5. Mol Diagn Ther. 2020. PMID: 31758333 Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials